Evonik in North America

A strong presence:

• approx. 5,000 employees
• 33 production sites
• 7 R&D centers

ESHQ:

• 0 Transportation Accidents
• 92.2 million metric tons of Greenhouse Gas Emissions avoided
• €37 million invested in environmental protection

Recent developments:

• In 2020, Evonik successfully closed the acquisition of PeroxyChem. PeroxyChem is a manufacturer of hydrogen peroxide (H₂O₂) and peracetic acid (PAA) and is well-positioned in high-margin specialty applications. PeroxyChem's H₂O₂ and PAA business focuses on end-users in the environmental, food safety, and electronics semiconductor industries.
• In 2019, Veramaris, a 50:50 joint venture of DSM and Evonik, began production of omega-3 fatty acids EPA and DHA from natural marine algae at Evonik’s Blair, Neb., facility. Veramaris’s breakthrough innovation – an algal oil – will, for the first time, enable the production of the omega-3 fatty acids EPA and DHA for animal nutrition without using fish oil from wild-caught fish, a finite resource.
• In 2018, Evonik began production at its new precipitated silica plant near Charleston, S.C. The company also transformed its Medical Devices Project House in Birmingham, Ala., into a competence center dedicated to collaborative R&D for specialty polymers In November, Evonik announced its intent to purchase Peroxychem, a manufacturer of hydrogen peroxide (H2O2) and peracetic acid (PAA) that is well positioned in high-margin specialty applications.
• In 2017, Evonik closed on its largest acquisition ever with the purchase of the specialty additives business of Air Products. The deal added about 600 employees and seven sites in North America, along with a portfolio of products uniquely compatible to Evonik’s. The company also purchased the silica business of J.M. Huber, bringing another almost 300 employees and three new sites to Evonik.